Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

tarheelpwg 40 posts  |  Last Activity: 14 hours ago Member since: Aug 15, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Anyone here knows ...

    by nascar.strong Apr 28, 2016 3:04 AM
    tarheelpwg tarheelpwg 14 hours ago Flag

    2.8 million not 1.8 milliion; below are morningstar figures for last three years. First Eagle must believe it's a good investment in human capital;all will be well if 907 is effective.

    Ali Fattaey/President and Chief Executive Officer - - 1,331,523(2013) 1,555,755(2014) 2,821,673(2015)

  • Reply to

    Anyone here knows ...

    by nascar.strong Apr 28, 2016 3:04 AM
    tarheelpwg tarheelpwg 18 hours ago Flag

    I see according to Morningstar that executive pay increased 14% in 2015, Fattaey, 2.8 million; Gray $822,877 and Viner $836,519. Gray and Viner departed; not bad compensation for a distressed biotechnology; huge risk here as the wait appears to have no end in sight. Curis is going to lack the money during the wait on 907; not sure where it can go to get cash to cover expenses.

  • Reply to

    Anyone here knows ...

    by nascar.strong Apr 28, 2016 3:04 AM
    tarheelpwg tarheelpwg Apr 28, 2016 9:20 AM Flag

    It all turns on the results of the 907 Ph2 trial which commenced in January. Do not know if dosing has begun at two recruitment centers. Should hear more detail at earnings conference which has yet to be scheduled, it should take place in early May.

  • Reply to

    No news and still rising.......

    by nboy1415 Apr 22, 2016 3:52 PM
    tarheelpwg tarheelpwg Apr 22, 2016 7:45 PM Flag

    lot of action in the last few seconds of trading day:

    NLS Time (ET) NLS Price NLS Share Volume
    16:00:01 $ 2.23 98
    16:00:01 $ 2.23 1,422
    16:00:01 $ 2.23 416
    16:00:01 $ 2.23 276
    16:00:01 $ 2.23 6,678
    16:00:01 $ 2.23 3,200
    16:00:01 $ 2.23 9
    16:00:01 $ 2.23 1,900
    16:00:01 $ 2.23 2,425
    16:00:01 $ 2.23 948
    16:00:01 $ 2.23 661
    16:00:01 $ 2.23 948
    16:00:01 $ 2.23 180
    16:00:01 $ 2.23 5,687
    16:00:01 $ 2.23 1,100
    16:00:01 $ 2.23 26
    16:00:01 $ 2.23 6
    16:00:01 $ 2.23 3,350
    16:00:01 $ 2.23 11,524
    16:00:01 $ 2.23 474
    15:59:59 $ 2.23 100
    15:59:58 $ 2.23 100
    15:59:58 $ 2.23 100
    15:59:57 $ 2.23 110
    15:59:57 $ 2.23 102
    15:59:57 $ 2.23 106
    15:59:55 $ 2.23 100
    15:59:55 $ 2.23 100
    15:59:55 $ 2.22 200
    15:59:54 $ 2.22 274
    15:59:54 $ 2.22 200
    15:59:54 $ 2.22 300
    15:59:54 $ 2.22 100
    15:59:54 $ 2.22 200
    15:59:54 $ 2.22 400
    15:59:54 $ 2.22 100
    15:59:54 $ 2.22 300
    15:59:54 $ 2.22 12,918

  • tarheelpwg by tarheelpwg Apr 21, 2016 4:29 PM Flag

    what explains this large block of shares being traded after hours today?

    After Hours Time (ET) After Hours Price After Hours Share Volume
    16:14 $ 2.11 High 76,699
    16:14 $ 2.11 High 672

  • Reply to

    Anybody been to AACR

    by nboy1415 Apr 20, 2016 4:13 PM
    tarheelpwg tarheelpwg Apr 20, 2016 7:05 PM Flag

    looks like it was a poster presentation,which I am assuming means no oral discussion from company officials; at around May 7th we will hear from CEO at quarterly earnings meeting.

  • Reply to

    Wednesday AACR presentation re: 907

    by tarheelpwg Apr 18, 2016 11:31 AM
    tarheelpwg tarheelpwg Apr 19, 2016 10:16 AM Flag

    agree, feel the air coming out of the tire again; the Aurigene partnership succeeded in raising capital, but that's about it; more than a year has passed and nothing to show for it.

  • Not sure what happens on the morning of April 20th at AACR; does someone discuss CRIS' abstract regarding the progress of 907? If history is a lesson, doubt the abstract is moving the price of the stock. I wonder if any of the patients being recruited at the Norton Cancer Center have been dosed? It seems pretty obvious that the fate of this company turns on the results of the monotherapy 907 Ph2 trial regarding MYC altered r/r hematological LDBCL patients.

  • Reply to

    New presentation!!!!!

    by nboy1415 Apr 13, 2016 12:10 PM
    tarheelpwg tarheelpwg Apr 13, 2016 2:56 PM Flag

    Nice work, your announcement of the new presentations sent the price up for a few hours. The NCT02674750 PH2 trial has a life of its own. So far only two sites have been identified, I am assuming there will be a third site, with 40 patients per site, 20 the monotherapy and 20 the rituximab combo. Do they wait until they have recruited all 120 before dosing? I am assuming they do not start dosage at the Louisville site until recruitment has been completed. The key news will be the success of 907 in treating those 20 patients recruited with MYC altered DLBCL in the monotherapy Ph2 trial, and it's anyone's guess how long that will be, certainly not before December. Maybe the Aurigene collaboration will bring some news, it's been over a year now since its announcement. True to form, however, the CA-150 IND will probably be delayed until the second half of the year.

  • Reply to

    AACR

    by tarheelpwg Apr 11, 2016 9:11 AM
    tarheelpwg tarheelpwg Apr 11, 2016 7:35 PM Flag

    I am not capable of viewing this company objectively as I have held for too long. I meant to say CRIS presentation at AACR shows promise that ph1 results will be favorable for solid tumors. Regarding Ph2 trial, by ASH in December we will know whether 907 getting same results as in Ph1. If they are the same, then drug will have to be taken seriously.

  • tarheelpwg by tarheelpwg Apr 11, 2016 9:11 AM Flag

    Should be informative, 907 making progress on the tumor front:
    "Significant antitumor effects have been consistently observed in MYC-driven DLBCL xenograft and genetically engineered mouse models exposed to CUDC907. In particular, certain MYC translocation (Daudi), double-hit (concurrent MYC and BLC2 translocation, WSUDLCL2 and DOHH2), double-expresser (expression of MYC and BCL2 proteins, U2932) xenograft models, and the Eµ-Myc transgenic mouse model achieve tumor growth inhibition of 100%, 69%, 56%, 97% and 72%, respectively.
    These findings raise the possibility that hematologic and solid tumors driven by aberrant overexpression of MYC family genes (e.g., MYC-altered DLBCL and NMC) might be more responsive to simultaneous HDAC and PI3K inhibition with CUDC-907 than they are to single-target therapy. Clinical Phase 1 studies are currently testing CUDC-907 in patients with relapsed/refractory (R/R) DLBCL and advanced MYC-aberrant solid tumors. Preliminary data are encouraging and support the planned Phase 2 study in R/R MYC-altered DLBCL, as well as further testing in other MYC-driven malignancies."

  • Reply to

    Jefferies Summit presentation?

    by tarheelpwg Apr 7, 2016 1:17 PM
    tarheelpwg tarheelpwg Apr 10, 2016 4:28 PM Flag

    looks like Curis was a no show; not confident they are presenting at AACR next week either; looks lie we have until ASH in December to wait for any definitive news on 907.

  • Curis expects that it will make presentations at the following investor and scientific conferences through April 2016:

    Cowen and Company 36th Annual Health Care Conference on March 7-9 in Boston, MA
    ROTH Capital Growth Conference on March 13-16 in Los Angeles, CA
    Jefferies 2016 Immuno-Oncology Summit on April 7-8 in Boston, MA
    American Association for Cancer Research (AACR) Annual Meeting on April 16-20 in New Orleans, LA

  • Recruiting at Oklahoma and Kentucky cancer treatment centers: regarding monotherapy trial, if we see positive results as good as or better than Ph1 trial, then Cris onto something as it appears there is an unmet need for treatment of MYC altered refractory/relapsed DLBCL patients. I wonder if CRIS has begun dosing. I am assuming it has not since recruiting is ongoing and that once completed it can begin dosing.

    Locations
    United States, Kentucky
    Norton Cancer Institute Recruiting
    Louisville, Kentucky, United States, 40207
    United States, Oklahoma

    Oklahoma Cancer Specialists and Research Institute, LLC Recruiting
    Tulsa, Oklahoma, United States, 74146

  • Reply to

    Lancet Oncology Publication

    by tarheelpwg Apr 4, 2016 7:51 AM
    tarheelpwg tarheelpwg Apr 4, 2016 11:16 PM Flag

    April 7th or 8th

  • Article does not appear to be telling us any more than what we already know. about Ph1 results. I am assuming the publication gives 907 credibility, however, in the eyes of the investment community. Should learn at Jefferies forum more about the status of the Ph2 trial.

  • Reply to

    Slow, slow, but moving up!

    by nascar.strong Mar 29, 2016 4:16 PM
    tarheelpwg tarheelpwg Mar 29, 2016 4:44 PM Flag

    you meant patience, but I will go with patients as with those currently being treated with CUDC-907 at the Norton Cancer Center in Louisville, Ky. At least I hope CRIS has begun the dosing and maybe close to completing the first 21 day cycle with the first group. Only if the results provide the same or greater percentage of CRs and PRs as those 8 with the MYC altered gene showed in PH1, then will there be appreciable move back to 3. Being the cynic I am, I expect CRIS to further postpone the IND regarding CA-170 until the second half of the year. I think Curis presents in mid-April at a Jefferies conference.

  • After Hours Time (ET) After Hours Price After Hours Share Volume
    17:34 $ 1.57 High 1,052
    16:19 $ 1.507 Low 111,985
    16:19 $ 1.507 Low 865
    16:12 $ 1.51 9,752
    16:00 $ 1.51 10,556
    16:00 $ 1.51 1,393

  • tarheelpwg tarheelpwg Mar 15, 2016 7:20 PM Flag

    Based on 907's Ph1 results, is the drug on the same trajectory to be as effective in treating refractory/relapsed DLBCL patients as CPXX has shown Vyxeos (sp) to be in treating AML patients?

  • Reply to

    Anyone Longs Still Here?

    by nascar.strong Mar 11, 2016 10:21 PM
    tarheelpwg tarheelpwg Mar 14, 2016 2:59 PM Flag

    I am preying we will have our GWPH moment in my lifetime; CEO said CRIS expects to present results on 907 ph2 at ASH in December, but was not committed as still time to file its abstract. Positive results will get this stock back over $5 and CRIS presenting at ASCO in June should have something to say about whether it will meets its deadline of filing an IND re: CA-170 by end of July which should at least get the traders fired up.

CRIS
2.039+0.009(+0.44%)10:23 AMEDT